Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)

Share on facebook
Share on twitter
Share on linkedin

Authors: Mustafa Acar, Prabhjot Juneja, Malcolm Handel
Open Access Rheumatology Research and reviews 2018:10

Related articles

Are high coronary risk patients missing ou...

To examine whether high coronary risk patients in Australia, where use of lipid-lowering drugs (LLD) is very high by international standards, are receiving LLD.

A retrospective review of the persistence ...

Aim: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD (cDMARD) concomitant me...